VIREXX COMPLETES DOSING IN HEPATITIS B VACCINE STUDY

ViRexx Medical has announced that enrolment and treatment has been completed in the Phase I trial of its HepaVaxx B Vaccine, the lead candidate from the company's Chimigen vaccine platform. The trial has enrolled and vaccinated its target of 15 healthy volunteers with a subcutaneous injection of HepaVaxx B Vaccine. There were no significant adverse events associated with the treatment.

The vaccine consists of a recombinant chimeric molecule containing a hepatitis B viral antigen and a portion of a murine monoclonal antibody. The molecule is designed to target dendritic cells, which play a significant role in antigen presentation and initiation of an immune response. In preclinical testing, HepaVaxx B Vaccine has produced both cellular and humoral immune responses. The company believes that the development of humoral and cellular responses may be effective in clearing the virus from patients with chronic hepatitis B infection.